Shanghai Allist Pharmaceuticals Co., Ltd. is a pharmaceutical company engaged in the research and development of tumor-targeted drugs in China and internationally. Its lead product is vometinib mesylate tablets for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). The company also develops pralatinib capsules and glerexyl citrate tablets for adult patients with locally advanced or metastatic NSCLC. Founded in 2004, it is based in Shanghai, China.
Allist Releases 2026 Interim Report with Net Profit of 1.541 Billion Yuan
Allist released its 2026 interim report on August 20, 2026. Total operating revenue was 3.32 billion yuan, net profit attributable to the parent company was 1.541 billion yuan, and net cash inflow from operating activities was 1.445 billion yuan. The company's latest asset-liability ratio was 10.38 percent, up 0.56 percentage points from the previous quarter. The latest gross margin was 94.85 percent, down 0.06 percentage points from the previous quarter and down 2.01 percentage points from the same period last year. The latest return on equity was 18.21 percent, and diluted earnings per share was 3.42 yuan. The company's latest total asset turnover was 0.38 times, and the latest inventory turnover was 2.16 times. The number of shareholders was 21,000, and the top ten shareholders held 266 million shares, accounting for 59.00 percent of the total share capital.
Multiple A-share companies disclose half-year reports and plan substantial dividends
On the evening of August 19, multiple A-share listed companies disclosed their half-year reports and planned substantial dividends. Dingtai High-Tech plans to distribute a cash dividend of 10 yuan per 10 shares, including tax, totaling 424 million yuan in cash dividends, including tax. Allist plans to distribute a cash dividend of 10 yuan per 10 shares, including tax, totaling 424 million yuan in cash dividends, including tax. Accelink Technologies plans to distribute a cash dividend of 3.7 yuan per 10 shares, including tax, totaling 306 million yuan in cash dividends, including tax. XTC New Energy Materials plans to distribute a cash dividend of 3 yuan per 10 shares, including tax, totaling 151 million yuan in cash dividends, including tax. HSC New Energy Materials plans to distribute a cash dividend of 3 yuan per 10 shares, including tax, totaling 46.4157 million yuan in cash dividends, including tax. Shanghai Airport plans to distribute a cash dividend of 2.7 yuan per 10 shares, including tax, totaling 672 million yuan in cash dividends, including tax. Hualu Hengsheng plans to distribute a cash dividend of 2.6 yuan per 10 shares, including tax, totaling 715 million yuan in cash dividends, including tax.
Allist's first-half net profit attributable to parent rises 46.6% to 1.54 billion yuan
Allist Pharmaceuticals released its 2026 interim report, with first-half net profit attributable to the parent company of 1.54 billion yuan, up 46.6% year on year. Operating revenue was 3.32 billion yuan, up 39.9% year on year. Net profit attributable to the parent after deducting non-recurring items was 1.37 billion yuan, up 51.0% year on year. Net operating cash flow was 1.445 billion yuan, up 32.2% year on year. Second-quarter operating revenue was 1.74 billion yuan, up 36.1% year on year, and net profit attributable to the parent was 905 million yuan, up 41.2% year on year. The company said that during the reporting period it focused on research and development of innovative oncology targeted therapies. Furmonertinib mesylate tablets received marketing approval for multiple indications, and the company introduced the KRAS G12C inhibitor glecirasib citrate tablets, with revenue from core products continuing to grow.
Allist Plans to Pay a Cash Dividend of 6 Yuan per 10 Shares
Allist announced plans to pay a cash dividend of 6 yuan, including tax, for every 10 shares to all shareholders, with an estimated total payout of 270 million yuan, accounting for 17.52 percent of net profit attributable to the parent company.
STAR Market Evening Bulletin: Pinzhun Laser joins the thousand-yuan stock club on debut day
Pinzhun Laser officially listed on the STAR Market today. Its issue price of 186.88 yuan set a new high for the year, and it closed the first day up 516.44 percent. The maximum floating profit for a single lot reached 556,600 yuan, topping the list of the most profitable new stocks in A-share history. The closing price of 1,152 yuan put it among A-shares trading above one thousand yuan. Puyu shares released its 2026 semi-annual report, achieving operating revenue of 3.959 billion yuan, up 336.67 percent year on year, and net profit attributable to shareholders of the listed company of 827 million yuan, up 1,929.65 percent year on year. The inclusion of SHM in the consolidated statements contributed 2.346 billion yuan in revenue. Allist responded to reports that furmonertinib mesylate tablets had been suspended from procurement by the Second Xiangya Hospital, saying it is verifying the authenticity of the reports and that all operations are currently normal. The actual controller of Espressif Systems proposed that the company buy back shares worth 100 million to 200 million yuan. Bluetrum reported first-half net profit of 480 million yuan, up 265.77 percent year on year. Spacesail completed a capital increase of nearly 7 billion yuan, bringing in 18 investors and reaching a valuation of 50 billion yuan.
STAR Market Healthcare ETF ChinaAMC Attracts 284 Million Yuan in 16 Days, Rises Over 1.4% Intraday
The STAR Market Healthcare ETF ChinaAMC rose 1.49% intraday, with its latest price at 1.02 yuan. The Shanghai STAR Market Biomedical Index it tracks also gained 1.49%. The ETF has seen net capital inflows for 16 consecutive trading days, totaling 284 million yuan, with an average daily net inflow of 17.72 million yuan. In related news, constituent stock Allist Pharmaceuticals released its 2026 half-year performance forecast, expecting net profit attributable to shareholders to grow 46.49% year-on-year to 1.54 billion yuan. RemeGen announced plans to repurchase shares at a price not exceeding 149 yuan per share, with an amount no less than 25 million yuan and no more than 50 million yuan. Century Securities believes that biomedicine is one of the few industries in China with full supply chain advantages, and suggests focusing on domestic innovative drug companies with validated platform capabilities in ADC and bispecific antibody fields.
Sci-Tech Innovation Board Healthcare ETF Huaxia (588130) offers retail investors a low-threshold gateway to the STAR Market healthcare sector
Sci-Tech Innovation Board Healthcare ETF Huaxia (588130) provides an alternative low-threshold path for retail investors who do not meet the account opening requirements for the STAR Market to participate in the board's biomedical sector. The ETF does not require STAR Market trading permissions; investors only need an ordinary A-share account or an on-exchange fund account to buy on the secondary market. The minimum trading unit is 100 shares, which at recent market prices amounts to around 100 yuan, whereas buying individual STAR Market stocks directly requires a minimum of 200 shares, often costing tens of thousands of yuan. The 588130 ETF tracks the SSE STAR Market Biomedical Index, offering one-click exposure to the top 50 biomedical companies by market capitalization on the STAR Market. The top ten holdings account for over 51% of the total, covering leaders in niche segments such as United Imaging Healthcare, BeiGene, and Allist Pharmaceuticals, with no single constituent exceeding 10% weight, balancing representation of leaders with risk diversification. As of July 16, 2026, the ETF's latest float size reached 323 million yuan, a new high over the past year, with an average daily turnover of 40.7485 million yuan over the last 20 trading days.
Penghua STAR Market Healthcare ETF Surges Over 4%, Capital, Policy, and Fundamentals Converge to Ignite Pharma Sector Rally
The pharmaceutical sector saw a broad-based rally, with the Penghua STAR Market Healthcare ETF climbing 4.12% to 1.12 yuan. The Shanghai STAR Market Biomedical Index it tracks surged 3.66%. Institutions note that this rebound is a value revaluation driven by a triple resonance of capital, policy, and fundamentals. The core driver is a shift of funds from the previously high-flying tech sector into innovative drugs, which have better prospects and are trading near bottom levels. On the policy front, the state continues to increase support for the entire innovative drug industry chain. On the fundamentals side, overseas business development deals keep materializing, with innovative drug BD deal values in the first half of 2026 hitting a new high despite the high base in the same period of 2025. Institutions believe that there is strong willingness for further capital allocation, and the pace of overseas commercialization is clear. Innovative drugs are the core investment theme for the pharmaceutical sector over the next three to five years, and this rebound is merely an initial warm-up. As of June 30, 2026, the top ten constituents of the Shanghai STAR Market Biomedical Index accounted for 51.84% of the total weight, including United Imaging Healthcare, Allist Pharmaceuticals, and BeiGene.
China